ガラクトオリゴ糖液糖の最大無作用量推定と安全性評価
スポンサーリンク
概要
- 論文の詳細を見る
To estimate the laxative threshold (LT) and 50% effective dose (ED_<50>) for diarrhea of a galactooligosaccharide (GOS) syrup (43% GOS ; 9.5% lactose ; 18% glucose ; 6.3% galactose ; 24% water), we asked 24 healthy subjects (12 men and 12 women ; age, 20 to 58 years ; weight, 39.0 to 96.0 kg) to ingest 190mL of aqueous solutions containing 5 different amounts (11.7,23.3,46.7, 70.0, 93.3g) of the syrup once every week from a low content to high one. Of the 24 subjects, 16 had diarrhea after ingestion of any test beverage. We estimeted the LT and ED_<50> of the GOS syrup by using a regression equation between the minimal dose levels (g/kg body weght) of the syrup caused diarrhea and the cumulative incidence of diarrhea. For the entire population, the estimated LT was 0.68 g/kg (0.30 g/kg as GOS) and the ED_<50> was 1.39 g/kg (0.60 g/kg as GOS). For men, the LT and ED_<50> were 0.65 g/kg and 1.13 g/kg, respectively, as compared with 0.90 g/kg and 1.50 g/kg for women. An increased frequency of bowel movements seemed to increase the incidence of diarrhea. The other abdominal symptoms reported were borborygmus (88%), flatus (58%), and abdominal distention (46%), all of which were transient, as was diarrhea. We also examined the safety of ingesting daily near amount of LT of the GOS syrup (15 g/person daily as GOS) for 2 weeks in 20 healthy adults. Although this dose increased the occurrence of abdominal gas in these subjects, the prevalence of diarrhea was unchanged as compared with that for the placebo beverage. These results show that the GOS syrup is safe even in repeated intake for near amount of LT.
- 日本食品化学学会の論文
- 2004-09-28
著者
-
柴田 英之
株式会社ヤクルト本社・ヤクルト中央研究所
-
松本 圭介
(株)ヤクルト本社中央研究所
-
木村 雅行
(株)ヤクルト本社中央研究所
-
池田 雅和
(株)ヤクルト本社中央研究所
-
柴田 英之
(株)ヤクルト本社中央研究所
-
池田 祥子
(株)ヤクルト本社中央研究所
-
SHIBATA Hideyuki
Yakult Central Institute for Microbiological Research
-
柴田 英之
ヤクルト本社 中研
関連論文
- 日本食からみる発酵食品の多様性と日本人の健康 : 肥満を中心に
- 沖縄モズク由来フコイダンの臨床的・基礎的検討
- GABA含有はっ酵乳製品の正常高値血圧者に対する降圧効果
- ヨーグルト中に生成するガラクトオリゴ糖の構造解析 : 食品
- ピリジルアミノ化法によるガラクトオリゴ糖の分析(3) : Bacillus circulans β-galactosidaseで調製したオリゴ糖の構造 : 食品
- ガラクトオリゴ糖液糖の最大無作用量推定と安全性評価
- ガラクトオリゴ糖の難消化性の検討
- ピリジルアミノ化法によるカラクトオリゴ糖の分析(4) : S. thermophilusのβ-galactosidaseによる乳糖転移反応について : 酵素
- γ-アミノ酪酸(GABA)含有はっ酵乳製品の健常成人に対する影響
- Ventures オキナワモズク由来fucoidanによるH. pylori低減効果について
- 沖縄モズク由来フコイダンの性状、定量法およびその効果について
- モズクフコイダンおよびウロン酸含有多糖の蛍光標識法およびHPLC分析法の検討
- モズク由来フコイダンの抗潰瘍効果について : 生体高分子・脂質
- モズク由来フコイダンの構造とHelicobactor pyloriに対する定着阻害作用について : 生体高分子・脂質
- Rare Activation of the Human c-Ha-ras Transgene of Mice in Hemangioendothelial Sarcomas and Liver Tumors Induced by Glu-P-1
- Hepatocellular Carcinoma Induction in LEC Rats by a Low Dose of 2-Amino-3, 8-Dimenthylimidazo[4,5-f]quinoxaline
- Formation and Removal of DNA Adducts in the Liver of Rats Chronically Fed the Food-borne Carcinogen, 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline
- 血圧降下作用を有するγ-アミノ酪酸含有発酵乳の研究開発
- Effects of a Soybean Isoflavone Mixture on Carcinogenesis in Prostate and Seminal Vesicles of F344 Rats
- Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac
- Cloning of Mongolian gerbil cDNAs encoding inflammatory proteins, and their expression in glandular stomach during H. pylori infection
- 槐花フラボノイドの相互作用によるPropionibacteriumに対する抗菌活性
- Oviposition behavior of the parasitoid fly, Bessa parallela (Meigen) (Diptera: Tachinidae), in the field
- Effects of temperature on immature development of the parasitic fly Bessa parallela (Meigen)(Diptera: Tachinidae)
- Inhibitory Effect of Cladosiphon Fucoidan on the Adhesion of Helicobacter pylori to Human Gastric Cells
- 新ガラクトオリゴ糖含有液糖がヒト腸内菌叢に及ぼす影響
- β1-4系ガラクトオリゴ糖の摂取が便秘傾向の健常人の便通及び便性改善に及ぼす影響